|Description||Igmesine is a selective σ1 receptor ligand (KD = 19.1 nM), with nearly no activity at σ2 receptors (IC50 > 1000 nM). It was developed by Pfizer. Igmesine inhibits the NMDA-induced increase in cGMP in a concentration-dependent manner and IC50 value is approximately 100 nM. Igmesine can weekly inhibit brain 5-HT uptake in vitro. It exhibits neuroprotective and antidepressant effects. No developments were reported for the treatment of Cognition disorders, Diarrhoea and Major depressive disorder.|
|Synonyms||Igmesine HCl; CI-1019; JO-1784;(+)-(E)-N-(Cyclopropylmethyl)-alpha-ethyl-N-methyl-alpha-(3-phenyl-2-propenyl)benzenemethanamine hydrochloride|
|Solubility||Soluble to 50 mM in DMSO|
|Application||Cognition disorders; Diarrhoea; Major depressive disorder|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Jouveinal; Pfizer|
CHIR 4531, an oligopeptides compound, has been found to be an opioid mu receptor agonist and was once studied in pain therapy.
Loperamide HCl is an opioid-receptor agonist with an ED50 of 0.15 mg/kg.
Nalfurafine is a selective and centrally-penetrant κ-opioid receptor (KOR) agonist without significant activity on μ- and δ-opioid receptors. With antipruritic ...
GSK-1521498 is a novel μ-Opioid receptor antagonist. It shows to attenuate reward-driven compulsive behaviours, such as stimulant drug seeking or binge eating i...
LY-190388 is an μ receptor agonist. It is a penicillamine-containing enkephalin analog and has analgesia effect.
Naloxegol oxalate is a CYP3A4 enzyme inhibitor, is a peripherally-selective opioid antagonist, for the treatment of opioid-induced constipation.
TRV130 is an oxaspiro compound that has been found to be a μ-opioid receptor G protein ligand and could be used in pain therapy. IC50: 8.1 (pEC50. G protein ass...
The racemate form of TRV130 which is an oxaspiro compound that has been found to be a μ-opioid receptor G protein ligand and could be used in pain therapy.
Cebranopadol is a novel first in class compounds with potent agonist activity on opioid receptor like -1(ORL-1) and the well established mu opioid receptor. lt ...
Endomorphin 1 is a high affinity (Ki = 360 pM) and highly selective agonist of theμ-opioid receptor with 4000- and 15000-fold preference over δ and κ respective...
The trihydrochloride salt form of MCOPPB, an effective full agonist of nociceptin receptor, could be a good antianxiety agent with few side-effects. pKi: 10.07.
Naltrexone, also called as Celupan, competitively antagonise μ, κ, δ, and σ-opioid receptors with the effect to reduce the occurrence of addictive behaviours .
TRV130 is an opioid drug that is under ｅvaluation in human clinical trials for the treatment of acute severe pain. It is a functionally selective μ-opioid recep...
Naltrindole hydrochloride is a cell permeable, potent and highly selective non-peptideδ opioid receptor antagonist (Ki= 0.02 nM) with 223- and 346-fold greater ...
LY-2456302, also called as CERC-501, is a potent, highly selective and centrally-penetrant kappa opioid receptor antagonist(Ki= 0.807 nM)with favorable pharmaco...
Trimebutine is an opioid receptor agonist used as spasmolytic agent abdominal pain.
Deltorphin 2, an anion transporting peptid, is a selective peptide agonist for theδ opioid receptor.
Endomorphin 2, an andogenous peptide, has high affinity and specificity for the μ-opioid receptor and displays reasonable affinities for kappa3 binding sites, w...
JNJ-20788560 is a delta opioid agonist analgesics. No recent reports of development identified for preclinical development in Inflammatory-pain in USA.
PZM21 is a potent Gi activator with exceptional selectivity for μOR (EC50= 1.8 nM) and minimal β-arrestin-2 recruitment.